Insight Molecular Diagnostics

Insight Molecular Diagnostics Inc. (iMDx), formerly Oncocyte Corporation, is a Nashville-based molecular diagnostics company focused on organ-transplant rejection monitoring. Its GraftAssure platform quantifies donor-derived cell-free DNA (dd-cfDNA) to detect early signs of transplant rejection, delivered today through CLIA-certified laboratory developed tests (GraftAssureCore) and positioned as an in vitro diagnostic kit (GraftAssureDx) under FDA review. The company rebranded from Oncocyte and moved its headquarters from Irvine, California to Nashville in June 2025, pivoting toward an estimated $1 billion transplant rejection testing market.